Down 4.3% In Last 12 Months, Can Danaher Stock Recover Through 2027?
Key Takeaways:
- Bioprocessing Strength: Consumables grew double digits in Q3 driven by robust monoclonal antibody production, offsetting equipment weakness.
- Price Projection: The stock could reach $254 by December 2027.
- Potential Gains: This target implies a 8% total return from the current price of $235.
- Annual Return: Investors could see roughly 4% annual growth over the next 1.9 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Danaher (DHR) delivered a strong third quarter, beating revenue, earnings, and cash flow expectations. The company posted 3% core revenue growth with sales reaching $6.1 billion, while adjusted earnings per share…
